Chronic Kidney Disease (CKD) is a syndrome in which continuous changes in kidney structure, function, or both with implications on the health of the individual occur. Examples of structural abnormalities are cysts, tumors, malformations and atrophy that are evident on imaging.
These changes are most frequently recognized by increased serum levels of creatinine, cystatin C, or blood urea nitrogen. Moreover, the most common pathological manifestation of CKD, regardless of the initiating insult or disease, is some form of renal fibrosis.
Chronic Kidney Disease Epidemiological Segmentation
The Epidemiological Segmentation of Chronic Kidney Disease in 7MM from 2017 to 2030 is segmented as:-
- Diagnosed Prevalent Cases of Chronic Kidney Disease
- Prevalent Cases of Chronic Kidney Disease by Stage
- Prevalent Cases of Chronic Kidney Disease by Etiologies
- Comorbidities Associated with Chronic Kidney Disease
- Dialysis Dependency in Chronic Kidney Disease
Chronic Kidney Disease Epidemiology
- The total prevalent population of Chronic Kidney Disease in 7MM in 2017 was 122,704,658
- The prevalent population of Chronic Kidney Disease in the United States in 2017 was 35,288,932
The market size of Chronic Kidney Disease in 7MM has been estimated to be USD 16,897.5 Million in 2030
Chronic Kidney Disease Market Drivers
- Advances and Future Research
- Increasing Prevalence of CKD
- Opportunities associated with CKD
- Early Detection and Precision Medicine
Chronic Kidney Disease Market Barriers
- Knowledge Gaps
- Disease Multiplier
- Limited Patient Education
- Threats associated with Comorbidities
Chronic Kidney Disease Emerging Drugs
The emerging drugs of the Chronic Kidney Disease market are
- Daprodustat
- Vadadustat
- Roxadustat
- Empagliflozin
- Veverimer
- Dapagliflozin
- Ziltivekimab
- Bardoxolone methyl
And many others.
Chronic Kidney Disease Key Players
The key players in the Chronic Kidney Disease market are
- GlaxoSmithKline
- Akebia Therapeutics
- FibroGen/Astellas Pharma/AstraZeneca
- Boehringer Ingelheim
- Tricida
- AstraZeneca
- Corvidia Therapeutics
- Reata Pharmaceuticals
And many others.